Galmed Pharmaceuticals Ltd. (GLMD)
NASDAQ: GLMD · Real-Time Price · USD
0.6960
-0.0341 (-4.67%)
At close: Jun 5, 2026, 4:00 PM EDT
0.6971
+0.0011 (0.16%)
After-hours: Jun 5, 2026, 6:40 PM EDT
Galmed Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
6
Market Cap
4.58M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| GeoVax Labs | 852.28K |
| CollPlant Biotechnologies | 389.00K |
| Pulmatrix | 3.00K |
| Virax Biolabs Group | 2.99K |
| Soligenix | 2.34K |
GLMD News
- 5 days ago - Galmed and Tissue Dynamics’ two-drug combination targets cardiac fibrosis - TheFly
- 5 days ago - Galmed and Tissue Dynamics’ two-drug combination targets cardiac fibrosis - TheFly
- 5 days ago - Tissue Dynamics and Galmed Unveil Unknown Metabolic Pathway for Cardiac Fibrosis and Heart Failure which Supports the Development of Aramchol for Cardiac Fibrosis - PRNewsWire
- 24 days ago - Galmed reports results from first-in-man PK study of Aramchol Meglumine - TheFly
- 24 days ago - Galmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 300mg - PRNewsWire
- 4 weeks ago - Galmed partnering with Tissue Dynamics to develop cardiac fibrosis platform - TheFly
- 4 weeks ago - Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics - PRNewsWire
- 7 weeks ago - Galmed announces research agreement with Ramot at Tel Aviv University - TheFly